N/A N=60 Platelet Rich Fibrin vs Sub Epithelial Connective Tissue and Coronally Advanced Flap Alone in Gingival Recession
Gingival Recession
Primary: Gingival Thickness — 1.97; 1.95; 1.39 millimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Single Stage Root Coverage for Gingival Recession With or Without Free Gingival Graft
Gingival Recession
Primary: Recession Height — 1.0; 0.9 mm
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
N/A N=34 Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites
Pain From Free Gingival Graft
Primary: Postoperative Pain as Assessed by Number of Participants With a Score of 0-3 (no to Minimal Pain) on a Visual Analog Scale — 12; 6 Participants — p=0.039
N/A N=30 Effectiveness of Modified-free Gingival Graft for Treatment of Localized Gingival Recession Defects
Gingival Recession, Localized
Primary: Mean Mid-facial Recession Coverage (mRC) — 60.7; 91.8 percentage
N/A N=35 PET/CT Imaging Companion Study To ACTG A5314
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR
Phase 3 N=584 Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
N/A N=23 Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Multiple Sclerosis
Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
N/A N=32 Induced Gingivitis & Intra-oral Imaging
Plaque Induced Gingivitis
Primary: Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index. — 0.6; 0.15 units on a scale
N/A N=28 The Evaluation Of The Efficiency Of Micro-osteoperforation
Crowding of Teeth
Primary: Rate of Mandibular Teeth Alignment — 4.27; 2.82; 2.08; 2.31 millimeter (mm)
N/A N=16 Comparison of Two Gingival Displacement Procedures
Gingival Retraction Techniques
Primary: Percentage of Errors in Impressions Made for Indirect Restorations — 85.7; 33.3; 28.6; 44.4 percentage of impressions
N/A N=69 IFI16 is a Periodontitis Modulating Protein
Severe Periodontitis · Acute Inflammatory Response
Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3
Phase 2 N=33 Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile
Smiling · Botulinum Toxins, Type A
Primary: Anterior Gingival Exposure (GE) 4 Weeks Post-injection — 3.6; 3.0 mm